(Source: Mauna Kea Technologies SA) f064dd70-0442-46f2-a24f-b7f71e49ad72.pdf MAUNA KEA TECHNOLOGIES AWARDED U.S. FDA CLEARANCE FOR USE OF CELLVIZIO IN MINIMALLY INVASIVE SURGERY 510(k) clearance supports use of Cellvizio endomicroscopy platform during a range of surgical procedures to treat many types of cancer New cleared indications reinforce Cellvizio in the new strategic partnership framework Paris, October 27, 2015 - Mauna Kea Technologies (Euronext: MKEA, FR0010609263, PEA-PME eligible), inventor of Cellvizio®, the multidisciplinary confocal laser endomicroscopy platform, today announced 510(k) clearance from the U.S. Food...
↧